Pharmafile Logo
Pharmafocus logo
Advanced Search

Cosentyx

Showing 15 posts of 34 posts found.

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

April 27, 2023
Business Services CHMP, Cosentyx, Dermatology, Novartis

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …

News
Press release
novartis_outside_1

Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis

August 3, 2020
Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …

News

UCB’s investigational IL-17A and IL-17F inhibitor outclasses Novartis’ Cosentyx in plaque psoriasis

July 24, 2020
Medical Communications, Research and Development Cosentyx, UCB, pharma, psoriasis

UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …

News
novartis_outside_1

Novartis’ Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study

June 4, 2020
Research and Development Cosentyx, Novartis, axial spondyloarthritis

New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the …

News
novartis_outside_1

EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis

April 29, 2020
Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …

News
abbvie_0

AbbVie’s Skyrizi outpaces Novartis’ Cosentyx in plaque psoriasis skin clearance

January 16, 2020
Research and Development AbbVie, Cosentyx, Novartis, Skyrizi, pharma, psoriasis

AbbVie has made it known that Skyrizi (risankizumab) outpaced Novartis’ Cosentyx (secukinumab) at Phase 3 in the treatment of plaque …

News

Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis

November 1, 2019
Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma

Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …

News
novartis_side_building

Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows

October 10, 2019
Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis

Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …

News

Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis

September 17, 2019
Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma

Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx …

News
novartis_side_building

Novartis provides promising update on Cosentyx in plaque psoriasis

June 26, 2019
Research and Development Cosentyx, Novartis, pharma, psoriasis

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that …

News
novartis_outside_1

Novartis’ Cosentyx approved in China for plaque psoriasis

April 2, 2019
Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis

Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …

News
novartis_side_building

Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial

March 5, 2019
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis

New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …

News
novartis_outside_1

Novartis doubles down on Cosentyx’s efficacy in psoriasis with extensive real-world data

September 13, 2018
Research and Development Cosentyx, Novartis, pharma, psoriasis

Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and …

News

Lilly posts promising P3 Taltz data

February 14, 2018
Research and Development Cosentyx, Eli Lilly, IL-17, Novartis, Taltz, biotech, drugs, pharma, pharmaceutical

The IL-17 market is a crowded space, and one dominated by Novartis’ Cosentyx. Eli Lilly is attempting to challenge that, …

News
novartis_outside_1

Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis

January 16, 2018
Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma

Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …

News

Latest content

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024

ANGLE signs commercial agreement with AstraZeneca

April 26, 2024

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024